275 related articles for article (PubMed ID: 27671334)
1. AXL Inhibition Suppresses the DNA Damage Response and Sensitizes Cells to PARP Inhibition in Multiple Cancers.
Balaji K; Vijayaraghavan S; Diao L; Tong P; Fan Y; Carey JP; Bui TN; Warner S; Heymach JV; Hunt KK; Wang J; Byers LA; Keyomarsi K
Mol Cancer Res; 2017 Jan; 15(1):45-58. PubMed ID: 27671334
[TBL] [Abstract][Full Text] [Related]
2. MERTK Mediates Intrinsic and Adaptive Resistance to AXL-targeting Agents.
McDaniel NK; Cummings CT; Iida M; Hülse J; Pearson HE; Vasileiadi E; Parker RE; Orbuch RA; Ondracek OJ; Welke NB; Kang GH; Davies KD; Wang X; Frye SV; Earp HS; Harari PM; Kimple RJ; DeRyckere D; Graham DK; Wheeler DL
Mol Cancer Ther; 2018 Nov; 17(11):2297-2308. PubMed ID: 30093568
[TBL] [Abstract][Full Text] [Related]
3. Dual Inhibition of MEK and AXL Targets Tumor Cell Heterogeneity and Prevents Resistant Outgrowth Mediated by the Epithelial-to-Mesenchymal Transition in NSCLC.
Konen JM; Rodriguez BL; Padhye A; Ochieng JK; Gibson L; Diao L; Fowlkes NW; Fradette JJ; Peng DH; Cardnell RJ; Kovacs JJ; Wang J; Byers LA; Gibbons DL
Cancer Res; 2021 Mar; 81(5):1398-1412. PubMed ID: 33402388
[TBL] [Abstract][Full Text] [Related]
4. AXL-Driven EMT State as a Targetable Conduit in Cancer.
Antony J; Huang RY
Cancer Res; 2017 Jul; 77(14):3725-3732. PubMed ID: 28667075
[TBL] [Abstract][Full Text] [Related]
5. AXL Inhibition Induces DNA Damage and Replication Stress in Non-Small Cell Lung Cancer Cells and Promotes Sensitivity to ATR Inhibitors.
Ramkumar K; Stewart CA; Cargill KR; Della Corte CM; Wang Q; Shen L; Diao L; Cardnell RJ; Peng DH; Rodriguez BL; Fan YH; Heymach JV; Wang J; Gay CM; Gibbons DL; Byers LA
Mol Cancer Res; 2021 Mar; 19(3):485-497. PubMed ID: 33172976
[TBL] [Abstract][Full Text] [Related]
6. Targeting AXL overcomes resistance to docetaxel therapy in advanced prostate cancer.
Lin JZ; Wang ZJ; De W; Zheng M; Xu WZ; Wu HF; Armstrong A; Zhu JG
Oncotarget; 2017 Jun; 8(25):41064-41077. PubMed ID: 28455956
[TBL] [Abstract][Full Text] [Related]
7. An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance.
Byers LA; Diao L; Wang J; Saintigny P; Girard L; Peyton M; Shen L; Fan Y; Giri U; Tumula PK; Nilsson MB; Gudikote J; Tran H; Cardnell RJ; Bearss DJ; Warner SL; Foulks JM; Kanner SB; Gandhi V; Krett N; Rosen ST; Kim ES; Herbst RS; Blumenschein GR; Lee JJ; Lippman SM; Ang KK; Mills GB; Hong WK; Weinstein JN; Wistuba II; Coombes KR; Minna JD; Heymach JV
Clin Cancer Res; 2013 Jan; 19(1):279-90. PubMed ID: 23091115
[TBL] [Abstract][Full Text] [Related]
8. AXL inhibition sensitizes mesenchymal cancer cells to antimitotic drugs.
Wilson C; Ye X; Pham T; Lin E; Chan S; McNamara E; Neve RM; Belmont L; Koeppen H; Yauch RL; Ashkenazi A; Settleman J
Cancer Res; 2014 Oct; 74(20):5878-90. PubMed ID: 25125659
[TBL] [Abstract][Full Text] [Related]
9. Targeting AXL and the DNA Damage Response Pathway as a Novel Therapeutic Strategy in Melanoma.
Flem-Karlsen K; McFadden E; Omar N; Haugen MH; Øy GF; Ryder T; Gullestad HP; Hermann R; Mælandsmo GM; Flørenes VA
Mol Cancer Ther; 2020 Mar; 19(3):895-905. PubMed ID: 31871265
[TBL] [Abstract][Full Text] [Related]
10. AXL kinase as a novel target for cancer therapy.
Wu X; Liu X; Koul S; Lee CY; Zhang Z; Halmos B
Oncotarget; 2014 Oct; 5(20):9546-63. PubMed ID: 25337673
[TBL] [Abstract][Full Text] [Related]
11. Targeting AXL and mTOR Pathway Overcomes Primary and Acquired Resistance to WEE1 Inhibition in Small-Cell Lung Cancer.
Sen T; Tong P; Diao L; Li L; Fan Y; Hoff J; Heymach JV; Wang J; Byers LA
Clin Cancer Res; 2017 Oct; 23(20):6239-6253. PubMed ID: 28698200
[No Abstract] [Full Text] [Related]
12. Therapeutic Activity of Anti-AXL Antibody against Triple-Negative Breast Cancer Patient-Derived Xenografts and Metastasis.
Leconet W; Chentouf M; du Manoir S; Chevalier C; Sirvent A; Aït-Arsa I; Busson M; Jarlier M; Radosevic-Robin N; Theillet C; Chalbos D; Pasquet JM; Pèlegrin A; Larbouret C; Robert B
Clin Cancer Res; 2017 Jun; 23(11):2806-2816. PubMed ID: 27923843
[No Abstract] [Full Text] [Related]
13. Axl receptor tyrosine kinase is up-regulated in metformin resistant prostate cancer cells.
Bansal N; Mishra PJ; Stein M; DiPaola RS; Bertino JR
Oncotarget; 2015 Jun; 6(17):15321-31. PubMed ID: 26036314
[TBL] [Abstract][Full Text] [Related]
14. Silencing AXL by covalent siRNA-gelatin-antibody nanoconjugate inactivates mTOR/EMT pathway and stimulates p53 for TKI sensitization in NSCLC.
Suresh D; Zambre A; Mukherjee S; Ghoshdastidar S; Jiang Y; Joshi T; Upendran A; Kannan R
Nanomedicine; 2019 Aug; 20():102007. PubMed ID: 31085346
[TBL] [Abstract][Full Text] [Related]
15. Dual inhibition of TGFβ and AXL as a novel therapy for human colorectal adenocarcinoma with mesenchymal phenotype.
Ciardiello D; Blauensteiner B; Matrone N; Belli V; Mohr T; Vitiello PP; Martini G; Poliero L; Cardone C; Napolitano S; De Falco V; Giunta EF; Ciaramella V; Corte CD; Barra G; Selvaggi F; Franco R; Marino FZ; Cuomo A; Morgillo F; Troiani T; Sibilia M; Ciardiello F; Martinelli E
Med Oncol; 2021 Feb; 38(3):24. PubMed ID: 33570712
[TBL] [Abstract][Full Text] [Related]
16. Single-Cell Proteomic Profiling Identifies Combined AXL and JAK1 Inhibition as a Novel Therapeutic Strategy for Lung Cancer.
Taverna JA; Hung CN; DeArmond DT; Chen M; Lin CL; Osmulski PA; Gaczynska ME; Wang CM; Lucio ND; Chou CW; Chen CL; Nazarullah A; Lampkin SR; Qiu L; Bearss DJ; Warner S; Whatcott CJ; Mouritsen L; Wade M; Weitman S; Mesa RA; Kirma NB; Chao WT; Huang TH
Cancer Res; 2020 Apr; 80(7):1551-1563. PubMed ID: 31992541
[TBL] [Abstract][Full Text] [Related]
17. AXL induces epithelial-to-mesenchymal transition and regulates the function of breast cancer stem cells.
Asiedu MK; Beauchamp-Perez FD; Ingle JN; Behrens MD; Radisky DC; Knutson KL
Oncogene; 2014 Mar; 33(10):1316-24. PubMed ID: 23474758
[TBL] [Abstract][Full Text] [Related]
18. Implication of the Receptor Tyrosine Kinase AXL in Head and Neck Cancer Progression.
von Mässenhausen A; Brägelmann J; Billig H; Thewes B; Queisser A; Vogel W; Kristiansen G; Schröck A; Bootz F; Brossart P; Kirfel J; Perner S
Int J Mol Sci; 2016 Dec; 18(1):. PubMed ID: 28025482
[TBL] [Abstract][Full Text] [Related]
19. AXL receptor as an emerging molecular target in colorectal cancer.
De Rosa L; Di Stasi R; Fusco V; D'Andrea LD
Drug Discov Today; 2024 Jun; 29(6):104005. PubMed ID: 38685399
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of the Receptor Tyrosine Kinase AXL Restores Paclitaxel Chemosensitivity in Uterine Serous Cancer.
Palisoul ML; Quinn JM; Schepers E; Hagemann IS; Guo L; Reger K; Hagemann AR; McCourt CK; Thaker PH; Powell MA; Mutch DG; Fuh KC
Mol Cancer Ther; 2017 Dec; 16(12):2881-2891. PubMed ID: 28904132
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
